Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 18/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30563641 | 1.00 | EPHX2 (0.49) | EPHX2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL29672603 | 0.86 | MEN1 (0.48) | EPHX2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5037099 | 0.79 | MEN1 (0.53) | EPHX2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9080547 | 0.73 | P2RX7 (0.44) | EPHX2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6897880 | 0.72 | EPHX2 (0.50) | EPHX2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL18970748 | 0.72 | TP53 (0.45) | EPHX2ALDH1A1 | |
| SCHEMBL30747769 | 0.71 | MEN1 (0.58) | EPHX2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL31399579 | 0.71 | DGKA (0.61) | EPHX2MEN1KMT2A | |
| SCHEMBL31399531 | 0.71 | DGKA (0.61) | EPHX2MEN1KMT2A | |
| SCHEMBL19032585 | 0.71 | DGKA (0.61) | EPHX2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331656-A1 | NANOMATERIALS COMPRISING ACETALS | BEAM THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331656-A1 | NANOMATERIALS COMPRISING ACETALS | BEAM THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2022140238-A1 | NANOMATERIALS COMPRISING ACETALS | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | LIPA, SGMS1, SGMS2 | EPHX2 318/4885MEN1 1394/4885KMT2A 1791/4885 |
| US-20230331656-A1 | NANOMATERIALS COMPRISING ACETALS | SGMS1, SGMS2, LIPA | EPHX2 1137/4885MEN1 1590/4885KMT2A 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.